Molbio Diagnostics Limited
Minimum investment
Bidding date
10 Aug - 12 Aug 2026
Price range
₹768 - ₹807
Minimum quantity
18
Minimum investment
₹13,824
Issue size
₹940 Cr.
IPO doc (link)
RHP docs
Listing exchange
NSE/BSE
Total Issue Size:
₹940 Crore
Fresh Issue: 21% (₹200 Cr)
OFS: 79% (₹740 Cr)
Fresh Issue – ₹200 Crore
Offer for Sale – ₹740 Crore
Before Issue: 46.65%
After Issue: 43.01%
Lock-in / Stabilization | Timeline |
|---|---|
Minimum Promoters' Contribution | 18 Months from the date of Allotment |
Remaining Pre-IPO Shareholding (Non-Promoter Eligible Shares) | 6 Months from the date of Allotment |
Anchor Investors (50% of Allocation) | 90 Days from the date of Allotment |
Anchor Investors (Remaining 50% of Allocation) | 30 Days from the date of Allotment |
Note: Retail IPO investors have no lock-in and can sell shares from the listing day.
Molbio Diagnostics Ltd., incorporated in October 2000, is a leading Indian molecular diagnostics company specializing in point-of-care (POC) diagnostic solutions. The company develops, manufactures, and commercializes rapid molecular testing platforms for infectious and non-communicable diseases, serving healthcare providers across India and more than 90 countries. The company's flagship Truenat platform is a portable, battery-operated PCR-based molecular diagnostics system designed to deliver accurate test results within an hour, making it particularly effective in remote and resource-limited healthcare settings. Truenat has gained global recognition, including WHO endorsement for tuberculosis (TB) molecular testing.
Molbio currently offers diagnostic solutions for over 30 diseases through 43 molecular assays, covering TB, COVID-19, HIV, Hepatitis B, Hepatitis C, HPV, and several other infectious diseases. Beyond molecular diagnostics, the company has expanded into radiology, digital pathology, and breast health screening through subsidiaries, partnerships, and strategic acquisitions. The company operates six manufacturing facilities across India and serves a diversified customer base including government healthcare programs, hospitals, diagnostic laboratories, research institutions, and international healthcare organizations. Its innovation-driven business is supported by strong research & development capabilities, an extensive patent portfolio, and internationally recognized quality certifications. As of March 31, 2026, Molbio Diagnostics employed 1,225 permanent employees across research, manufacturing, quality assurance, sales, finance, and corporate functions, making it one of India's prominent healthcare diagnostics technology companies.
Proprietary Truenat Technology: Molbio owns the Truenat molecular diagnostics platform, a differentiated technology that provides rapid and reliable PCR testing in decentralized healthcare settings.
Strong Research & Development: The company invests significantly in innovation, supported by an extensive patent portfolio and continuous product development.
Diversified Disease Portfolio: Molbio offers molecular testing solutions for more than 30 diseases, reducing dependence on a single product or therapeutic segment.
Global Customer Base: Operations across 90+ countries provide geographical diversification and long-term growth opportunities.
Recurring Revenue Model: The installed base of diagnostic machines generates repeat demand for consumables and testing kits, creating predictable recurring revenue.
Premium IPO Valuation: The IPO is priced at a relatively high valuation with a post-issue P/E of around 56.67x, which may limit upside if earnings growth slows.
Dependence on Government Healthcare Programs: A meaningful portion of revenue comes from government health initiatives. Changes in procurement policies or public healthcare spending could impact business performance.
Competitive Diagnostics Industry: The molecular diagnostics market is highly competitive with participation from both domestic and global healthcare companies, which could affect pricing and market share.
Regulatory Risk: The healthcare diagnostics industry is subject to stringent regulatory approvals and quality standards across different countries. Delays or regulatory changes may impact product launches.
Increasing Borrowings: Total borrowings increased from Rs. 123.16 crore in FY2025 to Rs. 412.64 crore in FY2026, which investors should monitor despite the company's improving profitability.
1 Cr.
Mar'26
164.14 Cr.
Mar'26
328.24 Cr.
Mar'26
57 investors voted
Active IPOs | |
|---|---|
Company name | Bid starts |
Leap India | 07-08-2026 |
Technocraft Ventures | 07-08-2026 |
Dhoot Transmission | 10-08-2026 |
Molbio Diagnostics | 10-08-2026 |
Milky Mist Dairy Food | 11-08-2026 |
Optimystix Entertainment India | 07-08-2026 |
Fascinate Textiles | 11-08-2026 |
